1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Progyny, Inc.
  6. Summary
    PGNY   US74340E1038

PROGYNY, INC.

(PGNY)
  Report
Real-time Estimate Cboe BZX  -  05/17 02:50:54 pm EDT
37.59 USD   +3.74%
05/11TRANSCRIPT : Progyny, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 08:40 AM
CI
05/06PROGYNY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
05/06The Broken Brown Egg and Progyny Launch the Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand their Families
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
33.06(c) 33.44(c) 36.94(c) 36.23(c) 37.16 Last
869 990 734 369 672 249 639 735 250 946 Volume
-2.36% +1.15% +10.47% -1.92% +2.57% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 757 M - -
Net income 2022 10,8 M - -
Net cash position 2022 210 M - -
P/E ratio 2022 192x
Yield 2022 -
Sales 2023 1 034 M - -
Net income 2023 38,7 M - -
Net cash position 2023 334 M - -
P/E ratio 2023 84,8x
Yield 2023 -
Capitalization 3 396 M 3 396 M -
EV / Sales 2022 4,21x
EV / Sales 2023 2,96x
Nbr of Employees 312
Free-Float 83,9%
More Financials
Company
Progyny, Inc. is a benefits management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company provides its benefit through its Smart Cycle approach. The Smart Cycle includes medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition, to its fertility benefits... 
More about the company
Ratings of Progyny, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PROGYNY, INC.
05/11TRANSCRIPT : Progyny, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-..
CI
05/06PROGYNY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/06The Broken Brown Egg and Progyny Launch the Awareness, Hope, and Activism Grant™ ..
GL
05/06Berenberg Bank Adjusts Progyny's Price Target to $66 From $70, Maintains Buy Rating
MT
05/05PROGYNY : Q1 Earnings Snapshot
AQ
05/05CORRECTION : Guidance: (pgny) progyny q1 eps $0.05
MT
05/05Earnings Flash (PGNY) PROGYNY Posts Q1 Revenue $172.2M, vs. Street Est of $167.2M
MT
05/05GUIDANCE : (PGNY) PROGYNY Sees Q2 EPS $0.05
MT
05/05TRANSCRIPT : Progyny, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Progyny, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05Progyny, Inc. Announces First Quarter 2022 Results
GL
05/05Progyny, Inc. Announces First Quarter 2022 Results
AQ
05/05Progyny, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022
CI
04/28Progyny, Inc. to Present at the BofA Securities 2022 Healthcare Conference
AQ
04/21Progyny, Inc. Announces Details for Its First Quarter 2022 Results Report
AQ
More news
News in other languages on PROGYNY, INC.
05/05Earnings Flash (PGNY) PROGYNY affiche un chiffre d'affaires de 172,2 millions de dollar..
05/05Progyny, Inc. annonce ses résultats pour le premier trimestre se terminant le 31 mars 2..
05/05Progyny, Inc. fournit des prévisions de bénéfices pour le deuxième trimestre et l'année..
04/06Malissia Clinton démissionne du conseil d'administration et du comité des nominations e..
03/02VENTE D'INITIÉS : Progyny
More news
Analyst Recommendations on PROGYNY, INC.
More recommendations
Chart PROGYNY, INC.
Duration : Period :
Progyny, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROGYNY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 36,94 $
Average target price 62,83 $
Spread / Average Target 70,1%
EPS Revisions
Managers and Directors
Peter Anevski Chief Executive Officer & Director
Michael Sturmer President
Mark Livingston Chief Financial Officer
David J. Schlanger Executive Chairman
Alan B. Copperman Medical Director
Sector and Competitors
1st jan.Capi. (M$)
PROGYNY, INC.-26.63%3 396
UNITEDHEALTH GROUP-3.33%455 388
ANTHEM, INC.4.94%117 276
CIGNA CORPORATION12.87%82 234
HUMANA INC.-5.38%55 517
CENTENE CORPORATION-0.10%48 148